Roche Venture Fund
Profile, fund size and portfolio
Roche Venture Fund is the corporate venture arm of F. Hoffmann-La Roche Ltd (pharmaceuticals and diagnostics). It was founded in 2002 and is based in Basel, Switzerland. It invests at Series A in pharmaceuticals, diagnostics, digital health.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Series A to Series A |
| Sectors | Pharmaceuticals, Diagnostics, Digital health |
| Geography | Europe, North America |
| Offices | Basel, Switzerland, South San Francisco, United States |
Sources: S4 Roche Venture Fund investing; S1 Roche Venture Fund home (fast facts).
Data behind this graphic
| Item | Companies | Share |
|---|---|---|
| Exited | 66 | 72.5% |
| Active | 25 | 27.5% |
Status as the firm tags it
Sources: S3 Roche Venture Fund portfolio (current and historic).
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | CHF 750M | Evergreen allocation | Stated by the firm or its parent | S1 |
| Companies backed | 30+ | companies | Stated by the firm | S3 |
| IPOs | 32 | IPOs | Stated by the firm | S3 |
| M&A exits | 34 | exits | Stated by the firm | S3 |
| Companies on the firm's portfolio page | 91 | companies | Counted from the firm's own list | S3 |
Sources: S1 Roche Venture Fund home (fast facts); S3 Roche Venture Fund portfolio (current and historic).
Where it invests and who leads it
Geography
- Headquarters
- Basel, Switzerland
- Offices
- Basel, Switzerland
- South San Francisco, United States
Investment regionsS4S1
- Europe
- North America
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | F. Hoffmann-La Roche Ltd | Single source | S1 |
| Parent industry | Pharmaceuticals and diagnostics | Single source | S1 |
| Founded | 2002 | Reported by aVenture: Roche Venture Fund research profile (launch year | S5 |
| Headquarters | Basel, Switzerland | Single source | S1 |
| Status | Active | Single source | S1 |
| Capital source | Parent company only | Single source | S1 |
| Headline size | CHF 750M (Evergreen allocation) | Single source | S1 |
| Companies backed | 30+ | Single source | S3 |
| Exits | 66 total, 32 IPOs, 34 M&A | Single source | S3 |
| People on the team page | 5 | Single source | S2 |
| Stages | Series A | Single source | S4 |
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
| Company | Type | Year | Acquirer or exchange | Price | Source |
|---|---|---|---|---|---|
| Afferent | Acquisition | Merck | S3 | ||
| Alios | Acquisition | Johnson+Johnson | S3 | ||
| Ambit | Acquisition | Daiichi Sankyo | S3 | ||
| Ambrx | Acquisition | Wuxi | S3 | ||
| Artus | Acquisition | Qiagen | S3 | ||
| Avexis | Acquisition | Novartis | S3 | ||
| BioFire | Acquisition | bioMérieux | S3 | ||
| BioXell | Acquisition | Cosmo | S3 | ||
| Care Innovations | Acquisition | PRA Health Sciences | S3 | ||
| CGI | Acquisition | Gilead | S3 | ||
| DVS | Acquisition | Fluidigm | S3 | ||
| Envoy | Acquisition | Takeda | S3 | ||
| Fabric Genomics | Acquisition | GeneDx | S3 | ||
| Flatiron | Acquisition | Roche | S3 | ||
| Foundation Medicine | Acquisition | Roche | S3 |
Portfolio
The firm's portfolio page lists 91 companies: 25 active, 66 exited.S3
The firm also states 30+ companies backed. The page list and the stated total measure different things.S3
| Tag | Companies | Share |
|---|---|---|
| Active | 25 | 27.5% |
| Exited | 66 | 72.5% |
Every company on the Roche Venture Fund list
91 companies, as listed on the firm's own website: 66 exited, 25 active.S3 Read the firm's list.
Exited 66
- 23andMe
- Addex
- Afferent
- Aileron
- Alios
- Allakos
- Ambit
- Ambrx
- Anadys
- Artus
- Avexis
- BioFire
- BioXell
- Black Diamond Therapeutics
- Blueprint Medicines
- C4 Therapeutics
- Caliper
- Care Innovations
- Centessa
- CGI
- Complete Genomics
- Conatus
- Corvus Pharmaceuticals
- Curetis
- CV Therapeutics
- CytomX
- deCode
- DVS
- Envoy
- Fabric Genomics
- Fibrogen, Inc
- Flatiron
- Foundation Medicine
- Good Therapeutics
- Halozyme Therapeutics
- HistoRx
- Horizon Discovery
- IDEAYA Biosciences
- Jasper Therapeutics
- Leukosite
- Lino Biotech
- LTI
- Lumos Pharma
- Maculogix
- Memory
- Miikana
- Miragen
- MySugr
- Nimble Therapeutics
- Pandion
- Pharmasset
- Protein Design Labs, Inc
- Purigen
- Second Genome
- Senseonics
- Sequana
- Stratos Genomics
- Syrrx
- Taimed
- Tango Therapeutics
- TiGenix
- Tripath
- Vaxcyte
- Viewics
- Xenon
- Zikanii
Active 25
- Aligos
- Bonum Therapeutics
- Civi Biopharma
- Cour
- DiogenX
- Enliven Therapeutics
- Enthera
- Entrada
- EpiBiologics
- Forcefield Therapeutics
- Freenome
- Glycoera
- Kumquat Biosciences
- Merge Therapeutics
- Minoryx
- Mironid
- Mission Therapeutics
- NMD Pharma
- Noema Pharma
- Receptive Bio
- River3Renal
- Sarepta Therapeutics
- SpliceBio
- Tempest Therapeutics
- Vivet Therapeutics
For founders
Fund vehicles
| Vehicle | Size | Year | Note | Source |
|---|---|---|---|---|
| Roche Venture Fund (evergreen) | CHF 750M | Evergreen; earlier descriptions cite CHF 500 million | S1 |
History
- Roche Venture Fund operates independently from 2002 (aVenture profile).S5
Where sources disagree
- Headline size: CHF 750M evergreen fund (firm site) (S1) vs CHF 500 million (earlier description in aVenture profile) (S5). Different dates.S1S5
- Portfolio count: More than 30 companies in the current portfolio (text on the page) (S3) vs 25 names listed under Current Investment Portfolio (S3). Text vs list.S3S3
Official pages
Read the firm's own pages for current information.
Sources
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Roche Venture Fund or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.